Finanzas de Acurx Pharmaceuticals Inc (ACXP)ACXPAcurx Pharmaceuticals Inc

Evaluating the bottom line, Acurx Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -128.11%, provide a clear picture of how effectively ACXP converts its operational activities into shareholder value.

In the context of the broader market, ACXP competes directly with industry leaders such as ERNA and BOLT. With a market capitalization of $7.59M, it holds a leading position in the sector. When comparing efficiency, ACXP's gross margin of N/A stands against ERNA's N/A and BOLT's 100.00%. Such benchmarking helps identify whether Acurx Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Acurx reported a net loss of $2.3 million for Q2 2026, with a diluted loss per share of $0.53, indicating ongoing financial challenges despite improvements in cash position.